Is there any potential management against COVID-19? A systematic review and meta-analysis.
Haleh Talaie,Sayed Masoud Hosseini,Maryam Nazari,Yadollah Fakhri,Atieh Mousavizadeh,Hossein Vatanpour,Ali Firoozfar +6 more
Reads0
Chats0
TLDR
All the included interventions significantly declined the mortality and enhanced clinical improvements with no effect on negative conversion and mechanical ventilation demand and especially, immunomodulators and plasma therapy showed favorable outcomes.Abstract:
A recent survey has shown that the COVID-19 pandemic has culminated in dramatical and critical treatment particularly in acute infected patients. In fact, this systematic review-meta-analysis was directly pertained to estimation at the efficient value of some clinical managements to confront the COVID-19 infection. Pubmed, Embase, Scopus, Cochrane, and Scholar databases were searched from inception to July 1, 2020, to identify studies reporting the current treatment process and medications (e.g. hydroxychloroquine, antiviral therapy, convalescent plasma, and immunomodulatory agents) for COVID-19. A random-effects model meta-analysis was performed to calculate the relative risk (RR) with 95% confidence intervals (CI). The outcomes of this study were the frequency of negative conversion cases, clinical improvements, mechanical ventilation demand, intensive care unit (ICU) entry, and mortality. The standard treatment refers to the published guidelines and specialist experience which varies in different articles, and the proposed treatment refers to the kind of interest suggested in the included studies. A number of 45 articles met the eligibility criteria (out of 6793 articles). Among them, 26 articles involving 3263 patients were included in quantitative analysis. Anti-COVID-19 interventions could significantly increase clinical improvement (RR 1.17, 95% CI 1.08–1.27; I2 = 49.8%) and reduce the mortality rate (RR 0.58, 95% CI 0.35–0.95; I2 = 74.8%). Although in terms of negative conversion, ICU entry, and mechanical ventilation demand, clinical intervention had no beneficial effect. The clinical effect of immunomodulatory agents (especially tocilizumab and anakinra) was noticeable compared to other medications with RR of 0.22 (95% CI 0.09–0.53; I2 = 40.9%) for mortality and 1.25 (95% CI 1.07–1.46; I2 = 45.4%) for clinical improvement. Moreover, Antivirals (RR 1.13, 95% CI 1.01–1.26; I2 = 47.0%) and convalescent plasma therapy (RR 1.41, 95% CI 1.01–1.98; I2 = 66.6%) had significant beneficial effects on clinical improvement. Based on our findings, all the included interventions significantly declined the mortality and enhanced clinical improvements with no effect on negative conversion and mechanical ventilation demand. Especially, immunomodulators and plasma therapy showed favorable outcomes.read more
Citations
More filters
Journal ArticleDOI
Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews.
TL;DR: In this paper, the authors summarize the evidence from the available systematic reviews on the efficacy and safety of convalescent plasma (CP) in COVID-19 through an overview of the published systematic reviews (SRs).
Journal ArticleDOI
Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis.
Valeria Conti,Graziamaria Corbi,Carmine Sellitto,Francesco Sabbatino,Chiara Maci,Nicola Bertini,Emanuela De Bellis,Antonio Iuliano,Sergio Davinelli,Pasquale Pagliano,Amelia Filippelli +10 more
TL;DR: In this paper, a meta-analysis aimed to assess TCZ effectiveness in reducing the mortality rate in COVID-19 patients was conducted. But, the authors found no statistically significant (p = 0.70) TCZ-related reduction of mortality regarding RCTs, while a significant reduction (log odds ratio = -0.41; 95% CI: -0., 0.68 −0.22, p < 0.001) was achieved regarding the observational studies.
Journal ArticleDOI
Convalescent Plasma for the Treatment of Severe COVID-19
TL;DR: In this article, the authors summarize the current evidence from the literature on the treatment of severe COVID-19 with convalescent plasma, and a concise overview of the hypothesized mechanisms of action is also presented.
Journal ArticleDOI
Features of patients that died for COVID-19 in a hospital in the south of Mexico: A observational cohort study.
Jesús Arturo Ruíz-Quiñonez,Crystell Guadalupe Guzmán-Priego,German Alberto Nolasco-Rosales,Carlos Alfonso Tovilla-Zárate,Oscar Israel Flores-Barrientos,Víctor Narváez-Osorio,Guadalupe del Carmen Baeza-Flores,Thelma Beatriz González-Castro,Carlos Ramón López-Brito,Carlos Alberto Denis-García,Agustín Pérez-García,Isela Esther Juárez-Rojop +11 more
TL;DR: Mexican individuals who died of COVID-19 had shorter hospital stays, higher frequency of shortness of breath, and higher prevalence of diabetes than individuals from other countries.
Journal ArticleDOI
Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis
Karolina Dahms,Agata Mikolajewska,Kelly Ansems,Maria-Inti Metzendorf,Carina Benstoem,Miriam Stegemann +5 more
TL;DR: The role of Anakinra in COVID-19 patients with elevated soluble urokinase plasminogen activator receptor (suPAR) remains unanswered, especially in patients receiving different forms of respiratory support as discussed by the authors .
References
More filters
Journal ArticleDOI
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +10 more
TL;DR: An Explanation and Elaboration of the PRISMA Statement is presented and updated guidelines for the reporting of systematic reviews and meta-analyses are presented.
Journal ArticleDOI
Quantifying heterogeneity in a meta‐analysis
TL;DR: It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.
Journal ArticleDOI
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
Julian P T Higgins,Douglas G. Altman,Peter C Gøtzsche,Peter Jüni,David Moher,Andrew D Oxman,Jelena Savović,Kenneth F. Schulz,Laura Weeks,Jonathan A C Sterne +9 more
TL;DR: The Cochrane Collaboration’s tool for assessing risk of bias aims to make the process clearer and more accurate.
Book
Cochrane Handbook for Systematic Reviews of Interventions
Julian P T Higgins,Sally Green +1 more
TL;DR: The Cochrane Handbook for Systematic Reviews of Interventions is the official document that describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of healthcare interventions.
The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
TL;DR: The Newcastle-Ottawa Scale (NOS) as discussed by the authors was developed to assess the quality of nonrandomised studies with its design, content and ease of use directed to the task of incorporating the quality assessments in the interpretation of meta-analytic results.